To investigate the risk factors for the occurrence of phlebitis after intravenous infusion therapy in children with Mycoplasma pneumoniae pneumonia. A total of 108 children with Mycoplasma pneumoniae pneumonia who received intravenous infusion therapy from December 2020 to December 2023 in our hospital were retrospectively analyzed. In the phlebitis group, the proportion of children with maximum body temperature ≥39℃ before treatment, the proportion of children with fever duration ≥3 days, and the proportion of children with combined pleural effusion were significantly higher (P < .05). Higher inflammation level before the initiation of treatment, longer duration of fever, and unsuccessful intravenous treatment are all risk factors for the occurrence of phlebitis in children with Mycoplasma pneumoniae pneumonia. Attention should be paid to the management of the whole process of intravenous infusion to reduce the incidence of this complication.
SongZJiaGLuoGHanCZhangBWangX.Global research trends of Mycoplasma pneumoniae pneumonia in children: a bibliometric analysis. Front Pediatr. 2023;11:1306234.
2.
LeungAKCWongAHCHonKL. Community-acquired pneumonia in children. Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):136-144.
3.
LingYZhangTGuoW, et al. Identify clinical factors related to Mycoplasma pneumoniae pneumonia with hypoxia in children. BMC Infect Dis. 2020;20(1):534.
4.
WaitesKBBalishMFAtkinsonTP.New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 2008;3(6):635-648.
5.
BianCLiSHuoS, et al. Association of atopy with disease severity in children with Mycoplasma pneumoniae pneumonia. Front Pediatr. 2023;11:1281479.
6.
AtkinsonTPBalishMFWaitesKB.Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956-973.
7.
XieQZhangXCuiWPangY.Construction of a nomogram for identifying refractory Mycoplasma pneumoniae pneumonia among macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children. J Inflamm Res. 2022;15:6495-6504.
8.
National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023 edition). China Licens Pharm. 2023;20(3):16-24. (In Chinese)
9.
Arias-FernándezLSuérez-MierBMartínez-OrtegaMD, et al. Incidencia y factores de riesgo de flebitis asociadas a catéteres venosos periféricos [Incidence and risk factors of phlebitis associated to peripheral intravenous catheters]. Enferm Clin. 2017;27(2):79-86.
10.
LiMWeiXZhangSS, et al. Recognition of refractory Mycoplasma pneumoniae pneumonia among Mycoplasma pneumoniae pneumonia in hospitalized children: development and validation of a predictive nomogram model. BMC Pulm Med. 2023;23(1):383.
11.
Meyer SauteurPMUngerWWNadalDBergerCVinkCvan RossumAM.Infection with and carriage of Mycoplasma pneumoniae in children. Front Microbiol. 2016;7:329.
12.
ParrottGLKinjoTFujitaJ.A compendium for Mycoplasma pneumoniae. Front Microbiol. 2016;7:513.
13.
GongHSunBChenYChenH.The risk factors of children acquiring refractory Mycoplasma pneumoniae pneumonia: a meta-analysis. Medicine (Baltimore). 2021;100(11):e24894.
14.
ChenWJChenQ.Progress of interleukin family expression in Mycoplasma pneumoniae pneumonia in children. J Trauma Emerg. 2023;11(03):113-116+120. (In Chinese)
15.
KuttyPKJainSTaylorTH, et al. Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia. Clin Infect Dis. 2019;68(1):5-12.
16.
ZhaoJLWangXWangYS.Relationships between Th1/Th2 cytokine profiles and chest radiographic manifestations in childhood Mycoplasma pneumoniae pneumonia. Ther Clin Risk Manag. 2016;12:1683-1692.
17.
LeeYCChangCHLeeWJ, et al. Altered chemokine profile in refractory Mycoplasma pneumoniae pneumonia infected children. J Microbiol Immunol Infect. 2021;54(4):673-679.
18.
BiYZhuYMaX, et al. Development of a scale for early prediction of refractory Mycoplasma pneumoniae pneumonia in hospitalized children. Sci Rep. 2021;11(1):6595.
19.
XuXFLiXJLiuJLWuLChenZM.Serum cytokine profile contributes to discriminating M. Pneumoniae pneumonia in children. Cytokine. 2016;86:73-78.
20.
WangHHZouYX.Research progress in mechanisms of drug-resistance of macrolide antibiotics resistance in Mycoplasma pneumoniae. J Clin Med Pract. 2023;27(12):136-140+148. (In Chinese)
21.
IramainRDe JesúsRSpittersC, et al. Chlamydia pneumoniae, and Mycoplasma pneumoniae: are they related to severe asthma in childhood?J Asthma. 2016;53(6):618-621.
22.
ChenYYaoHYWangP, et al. Study on early prediction indexes of severe Mycoplasma pneumoniae pneumonia in children. Matern Child Health Care China. 2024;39(02):239-242. (In Chinese)
23.
WeiJWuSJinXZhangJPanS.Association of Mycoplasma pneumoniae coinfection with adenovirus pneumonia severity in children. Allergol Immunopathol (Madr). 2022;50(1):31-36.
24.
TongLHuangSZhengCZhangYChenZ.Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management. J Clin Med. 2022;11(10):2824.
25.
ZhouYWangJChenW, et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2020;20(1):633.
26.
LitaoMKKamatD.Erythrocyte sedimentation rate and C-reactive protein: how best to use them in clinical practice. Pediatr Ann. 2014;43(10):417-420. doi:10.3928/00904481-20140924-10.
